Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effects of an Estrogen Receptor (ER) Beta Agonist (Lilly Compound LY500307) on Estradiol-withdrawal-induced Mood Symptoms in Women With Past Perimenopausal Depression.

Trial Profile

The Effects of an Estrogen Receptor (ER) Beta Agonist (Lilly Compound LY500307) on Estradiol-withdrawal-induced Mood Symptoms in Women With Past Perimenopausal Depression.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Erteberel (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Feb 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 6 Feb 2019 to 14 Feb 2019.
    • 31 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Jan 2019 to 6 Feb 2019.
    • 25 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 3 Jan 2019 to 31 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top